Appendix Table E62. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of Multiplate Analyzer

|  | **Demographics** | **Vascular disease history** | **Vascular risk factors** | **Prior medications****(pre-study)** | **Procedural data** | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medication** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year [ref]****UID****Country****Study Name** | **Total N Enrolled** **Race (% by group)****Male (%)****Age\*** | **Previous CAD (%)****Previous heart failure(%)****Previous TIA/stroke(%)****History of PCI or CABG(%):****Stable angina(%)****Unstable angina(%)****Previous PAD(%)****History of MI(%)****STEMI/non-STEMI(%)** | **Dyslipidemia (%)****Smokers (%)****BP(mmHg diastolic/systolic** **HTN (%)****Diabetes (%)** | **Vitamin K antagonist(%)****Clopidogrel(%)****Aspirin(%)****PPI(%)** | **Stent implantation(%)****Type of stent(%)****Multi-or single vessel(%)**  |  |  |  |
| Siller-Matula, 200919135705AustriaNR | 30NR8463±10 | 100NRCVD 7PCI 43NRNR1037NR | hyper 7757HTN 7733 | NR100100NR | NRNRNR | not used | Patients had been on chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) treatment for three months on average.  | All patients received unfractionated heparin and 250 mg of injectable acetyl-salicylic acid during PCI  |
| Ko, 201121315223KoreaNR | 222?Asian 152 (69)63.3 ± 10 | 100NRCVA: 14.9PCI: 37 (16.7); CABG: 1 (0.5)NRNRNR5.9NSTEMI: 10.1 | Hypercholesterolemia: 46.8Current: 12.2HTN: 72.132 | NR72.189.6NR | 100Drug elutingMulti-vessel; Stents/pt: 1.8±1 | Patients undergoing percutaneous coronary intervention (PCI) for CAD | All patients were pretreated with aspirin (100 mg/d) and clopidogrel (75 mg/d) at least 5 days before PCI or received oral loading doses of 250 mg aspirin and 300 mg clopidogrel 12 to 24 hours before PCI.Maintenance doses of 100 mg aspirin and 75 mg clopidogrel after PCIAfter PCI, dual antiplatelet therapy with 100 mg/d aspirin and 75 mg/d clopidogrel was continued for at least 6 months | NR |
| Sibbing, 201019943882Sibbing, 201020633826GermanyNR | 2533NR2034 (80.3%)mean: 67.8 | NRNRNRCABG: 14.3%NRNRNR31.4NSTEMI/STEMI: 14.5% | Hypercholesterolemia: 68.4%Active: 13.2%Arterial HTN:90.6%28.6% | 10.9%Thienopyridine: 41.3%74.3NR | Stents per lesion: 1.3; Lesions per patient: 1.9NRMultivessel disease: 85.5% | Patients undergoing PCI with stenting for ACS and CAD | Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MDAspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD | PCI: Intravenous anticoagulant: unfractionated heparin or bivalirudin (140 U/kg body weight for unfractionated heparin and for bivalirudin with a dosing regimen of 0.75 mg/kg body weight for bivalirudin before PCI, followed by an infusion of 1.75 mg/kg/h bivalirudin for the procedure); Some pts received glycoprotein IIb/IIIa inhibitor abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 μg/kg/min infusion for 12 h) with reduced heparin dose |
| Sibbing, 200919264241 Sibbing, 201020062919GermanyNR | 1608NR1234 (77%)67.5±40.5 | NRNRNRCABG: 14%NRNRNR32NR | Hypercholesterolemia: 70%Active: 13%HTN: 91.6%29 | NRNR99.1NR | NRNRNR | Patients undergoing PCI with stenting for ACS and CAD | Clopidogrel: 600 mg LD + 150 mg/day clopidogrel for 3 days + 75 mg/day clopidogrel MDAspirin: 500 mg IV LD + 100 mg aspirin (twice per day) MD | PCI: Intravenous anticoagulant: unfractionated heparin or bivalirudin (140 U/kg body weight for unfractionated heparin and for bivalirudin with a dosing regimen of 0.75 mg/kg body weight for bivalirudin before PCI, followed by an infusion of 1.75 mg/kg/h bivalirudin for the procedure); Some pts received glycoprotein IIb/IIIa inhibitor abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 μg/kg/min infusion for 12 h) with reduced heparin dose |
| Schulz, 201020691843GermanyNR | 1608NR1234 (76.7%)67.4 | NRNRNRCABG: 14.4%66.922.2NR31.5STEMI: 2.5%; NSTEMI: 8.4% | Hypercholesterolemia: 69.8%Active: 13.4%HTN: 91%28.7 | NRNRNRNR | 94.8%BMS: 2.2%; DES: 92.6%Multivessel: 85.1% | patients undergoing PCI | 600 mg clopidogrel before PCI and 500 mg aspirin LD directly before the intervention;Postinterventional therapy : clopidogrel 75 mg twice daily for 3 days, then 75 mg per day for 6 months with aspirin 100 mg twice daily | Periprocedural therapy: unfractionated heparin (as a bolus of 140 U/kg bodyweight) or bivalirudin (0.75 mg per kg bodyweight bolus, followed by an infusion of 1.75 mg per kg bodyweight per hour for the duration of the procedure) or abciximab (0.25-mg/kg bodyweight bolus, followed by an infusion of 0.125 μg/kg bodyweight per min for 12 hours) along with 70 U/kg bodyweight unfractionated heparin |
| Freynhofer, 201121614416AustriaNR | 300NR20562±16 | 43.3NRNRPCI 24.3NRsee UA/NSTEMI1022.729.7/34.3 | hyper 69.327.3HTN 74.727.3 | NR10010081.3 | 100DES 65.3multi-vessel 58.7 | PCI and coronary stenting | Clopidogrel-naïve patients received a 300 or 600 mg loading dose (LD). Patients on chronic clopidogrel therapy with 75 mg clopidogrel of at least seven consecutive days did not receive an additional LD.  | According to actual evidence, all patients received in parallel ASA (100 mg daily dose). The use of GP-IIb/IIIa-blockers during PCI as well as the choice of the anticoagulant depended on the individual situation and the thrombus load at angiography, and was left to the discretion of the operator |
| Siller-Matula, 201019943879AustriaNR | 416NR7664±12 | 100NRNR47NRNR1333NR | hyper 76558532 | NR10010077 | 99NRNR | PCI with stenting | Clopidogrel loading dose at least 2 hr before PCI (600 mg); thereafter, a daily dose of 75 mg, with planned treatment with clopidogrel and aspirin for at least 6 months.  | Also all patients received unfractionated heparin (100 IU per kg) during PCI and 250 mg aspirin intravenously immediately after stent placement (and daily dose of 100 mg thereafter). |
| Eshtehardi, 201020435201SwitzerlandNR | 219NR168 (77%)Mean/SD 66+/-9 yr | NRACS 82 (37%) [not sure ACS=heart failure]NRPCI 70 (32%); CABG 26 (12%)137 (63%)NRNR60 (27%)NR | 155 (71%)Current 57 (26%)Atrial HTN 163 (74%)43 (20%) | NR100%; (pretreatment in study)100% (pretreatment in study)NR | NR1DES 164 (75%); BMS 55 (25%)Multi 77 (34%) | Patients with stable angina or ACS with an indication for PCI, undergoing PCI with stenting | 500 mg ASA intravenously (unless if already on 100 mg daily); then 600 mg clopidogrel loading dose (unless already on 75 mg daily) | unfractionated heparin (70-100 U/kg body weight) before or at time of PCI |
| Ivandic, 200919359538GermanyNR | 182 (163 full responders, 19 dual nonresponders)NR130 (71%)Median age (95% CI); Nonresponders 68 (59–72); Responders 65 (67–72) | NRNRNRNR78 (43%)14 (8%)NRNR40 (22%)/52 (29%) | Hypercholesterolemia 113 (82%)61 (34%)HTN (arterial) 146 (80%)57 (31%) | NR100%100%NR | 100%DES only 77 (42%); BMS only 75 (41%); Both 23 (13%)3-vessel 90 (49%) | CAD patients who underwent PCI | Emergency patients with ACS received 0.5 g ASA intravenously and an oral loading dose of 600 mg clopidogrel before PCI. Electively hospitalized patients with suspected CAD or suspected progression of CAD received 0.5 g ASA intravenously before and loading dose of 600 mg clopidogrel immediately after PCI and stenting. After PCI, all patients received maintenance doses of 100 mg ASA and 75 mg clopidogrel once daily. | A single bolus of unfractionated heparin (10 000 U) was given immediately before PCI. The type of stent used for PCI was left at the discretion of the operator. |
| Siller-Matula, 201222260716PEGASUS-PCI | 416NR7664±12 | NRNRNRPCI 47NRNR133118/NR | hyper 76558432 | NR10010076 | 100DES 99NR | patients undergoing PCI | clopidogrel LD 600mg, MD 75mg | NR |
| Codner, 201222534051IsraelNR | 57NR9154.5 | 7NRNRPCI-16/CABG-7%NRNRNR18NR | 58394519 | NRNRNRNR | NRNRNR | PCI for ACS | LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d | heparin, bivalirudin, and/or glycoprotein IIb/IIIa inhibitors |
| Gerotziafas, 201222311629GreeceNR | 106NR84.963.3 | NRNRNRPCI - 71% NRNRNRNRNR | 53.817.984.918.9 | NR100100NR | NRNRNR | PCI for ACS | aspirin100 mg and clopidogrel 75 mg once daily | NR |
| Johnston, 201222465351New ZealandNR | 250European 81.277.767.6 | 77.767.6NRNRNRPCI=38.3/CABG-14%NRNRNR19.1NR | 70.62289.431.2 | NR100100NR | NRNRNR | PCI for ACS | aspirin ≥300 mg at and clopidogrel≥300 mg and/or aspirin (≥75 mg) and clopidogrel (≥75 mg) | NR |
| Sibbing, 201222682553GermanyISAR-REACT 4 | 56481.274.862 | NRNRNRPCI-18/CABG-8NRNRNR22.4NR | 54.8265820.8 | NRNRNR26 | NRNRNR | PCI for ACS | LD: 600 mg of clopidogrel and 500 mg aspirin MD: clopidogrel 75 mg x 12 months and aspirin 100 mg twice daily for an indefinite period | Abciximab plus UFH group: bolus of 0.25 mg abciximab and 70 units UFH per kilogram body weight; then continuous infusion of 0.125 µg abciximab per kilogram body weight per minute x 12 h. Bivalirudin group: bolus of 0.75 mg per kilogram bivalirudin, followed by a continuous infusion of 1.75 mg per kilogram per hour during PCI. |
| Siller-Matula, 201222305813AustriaNR | 403NR75.964.3 | 100NR10.2PCI=46.9NRNR12.432NR | 76.455.1NR8524 | NRNR10078.4 | 100DES-99%NR | Elective PCI for CAD | LD clopidogrel 600 mg 2 h pre PCI, 100 mg aspirin intake ; Additionally 250 mg acetylsalicylic acid i.v. directly before stent placementMD: 75 mg clopidogrel; 100 mg aspirin for 12 months | unfractionated heparin 100 IU/kg before PCI |

\*Mean (standard deviation), unless otherwise stated.
**Abbreviations:** ACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, MI = myocardial infarction; NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack